强力定眩胶囊联合左旋氨氯地平治疗高血压的临床研究

Clinical study on Qiangli Dingxuan Capsules combined with levamlodipine in treatment of hypertension

目的评价强力定眩胶囊联合左旋氨氯地平治疗高血压的临床疗效与安全性。方法选取重庆市第五人民医院2014年1月—2017年5月收治的高血压患者181例,随机分为对照组(90例)和治疗组(91例)。对照组患者口服苯磺酸左旋氨氯地平片,1片/次,1次/d;治疗组患者在对照组的基础上口服强力定眩胶囊,4片/次,3次/d。两组患者均连续治疗1个月。观察两组患者临床疗效,同时比较治疗前后两组患者收缩压、舒张压、脉搏波传到速度(PWV)水平、颈动脉内中膜厚度(IMT)值和不良反应情况。结果治疗后,对照组临床总有效率为87.78%,显著低于治疗组的96.70%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者的收缩压和舒张压比治疗前均显著降低(P<0.05),且治疗后治疗组比对照组降低的更明显(P<0.05)。治疗后,两组患者的PWV水平和颈动脉IMT值比治疗前均显著降低(P<0.05),且治疗后治疗组PWV水平和颈动脉IMT值明显低于对照组(P<0.05)。治疗期间,治疗组患者不良反应发生率为2.20%,显著低于对照组的10.99%,两组患者比较差异具有统计学意义(P<0.05)。结论强力定眩片联合左旋氨氯地平治疗高血压效果显著,安全性好,具有一定的临床推广应用价值。

Objective To evaluate the clinical efficacy and safety of Qiangli Dingxuan Capsules combined with levamlodipine in treatment of hypertension. Methods Patients（181 cases） with hypertension in the Fifth People’s Hospital of Chongqing from January 2014 to May 2017 were randomly divided into control（90 cases） and treatment（91 cases） groups. Patients in the control group were po administered with Levamlodipine Besylate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Qiangli Dingxuan Capsules on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the systolic and diastolic blood pressure, the serum PDGF-BB levels and carotid IMT values, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 87.78%, which was significantly lower than 96.70% in the treatment group, and there were differences between two groups（P 〈 0.05）. After treatment, the systolic and diastolic blood pressure in two groups was significantly decreased（P 〈 0.05）, and the index in the treatment group after treatment was significantly lower than that in the control group（P 〈 0.05）. After treatment, the PWV level and IMT value in two groups were significantly decreased（P 〈 0.05）, and the PWV level and IMT value in the treatment group after treatment were significantly lower than those in the control group（P 〈 0.05）. During the treatment, the adverse reactions rate in the treatment group was 2.20%, which was significantly lower than 10.99% in the control group, with significant difference between two groups（P 〈 0.05）. Conclusion Qiangli Dingxuan Capsules combined with levamlodipine in treatment of hypertension has significant clinical efficacy with high safety, which has a certain clinical application value.